SCHEMBL2121920

SCHEMBL2121920

COc1ccc(S(=O)(=O)N(Cc2ccccc2)c2ccccn2)cc1

nearest known ligand 0.76

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.76
SMN1; SMN2 Q16637 1/20 0.76
KDM4E B2RXH2 4/20 0.65
LMNA P02545 2/20 0.62
NR3C1 P04150 1/20 0.62
PGR P06401 1/20 0.62
NPSR1 Q6W5P4 1/20 0.62
HPGD P15428 2/20 0.61
HSD17B10 Q99714 1/20 0.61
MMP9 P14780 7/20 0.56
MMP1 P03956 6/20 0.56
MMP13 P45452 6/20 0.56
CNR1 P21554 1/20 0.56
CNR2 P34972 1/20 0.56
TRPM8 Q7Z2W7 1/20 0.55
MAPT P10636 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2120000 0.87 ALDH1A1 (1.00) ALDH1A1SMN1; SMN2KDM4ENR3C1HPGD
SCHEMBL2116993 0.86 ALDH1A1 (0.82) ALDH1A1SMN1; SMN2KDM4ELMNANR3C1
SCHEMBL7821932 0.84 KEAP1 (0.65) KDM4E
SCHEMBL2117002 0.83 ALDH1A1 (0.82) ALDH1A1SMN1; SMN2KDM4ELMNANR3C1
SCHEMBL2118378 0.83 ALDH1A1 (0.82) ALDH1A1SMN1; SMN2KDM4ENR3C1PGR
SCHEMBL2122260 0.80 ALDH1A1 (0.76) ALDH1A1SMN1; SMN2KDM4ELMNANR3C1
SCHEMBL2117044 0.79 GAA (0.71) ALDH1A1SMN1; SMN2KDM4ENR3C1HPGD
SCHEMBL2196203 0.78 LMNA (0.67) ALDH1A1LMNANR3C1PGRNPSR1
SCHEMBL28282357 0.78 ALDH1A1 (0.54) ALDH1A1SMN1; SMN2KDM4ELMNANR3C1
SCHEMBL20485813 0.78 KDM4E (0.57) ALDH1A1SMN1; SMN2KDM4ELMNANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120094964-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2012-04-19 US disclosed
US-20120094964-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2012-04-19 US disclosed
US-20120094964-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2012-04-19 US disclosed
WO-2010125831-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2010-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120094964-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS TRPM8, TRPM5, TRPM6 ALDH1A1 1996/4885SMN1; SMN2 1501/4885KDM4E 2411/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.